Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



From the category archives: OBN News

Company announcement

Immune cell regulation company MiroBio relocates to The Oxford Science Park

MiroBio was spun out in 2019 from the laboratories of Simon Davis, Professor of Molecular Immunology at the MRC Weatherall Institute of Molecular Medicine, and Richard Cornall, Nuffield Professor of Clinical Medicine at the University of Oxford.

Read the rest of entry »

Newcells Biotech scales up its operations in The Biosphere in Newcastle

Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory sites into 500m2 of laboratory and co-located office space in The Biosphere, which forms part of the Newcastle Helix cluster.

Read the rest of entry »

Leaf Expression Systems Aids Research into the Novel Coronavirus (SARS-CoV-2, 2019-nCoV) with the Development of Recombinant SARS-CoV-2 N-Protein

Leaf Expression Systems (Leaf), announces that it has developed a recombinant SARS-CoV-2 N-protein (antigen) to aid research into the Novel Coronavirus (SARS-CoV-2, 2019-nCoV) pandemic

Read the rest of entry »

Arecor Presents Positive Results for the First Phase I Clinical Trial of AT247, a Novel Ultra-Rapid Acting Insulin

Arecor Presents Positive Results for the First Phase I Clinical Trial of AT247, a Novel Ultra-Rapid Acting Insulin.  AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp®

Read the rest of entry »

Arecor announces the oral presentation of the first Phase I Clinical Trial of AT247, a novel Ultra Rapid Insulin Formulation, at the American Diabetes Association 80th Scientific Sessions

Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I Study Investigating the PD, PK and Safety of AT247 in comparison with NovoRapid® and Fiasp®’, has been selected for oral presentation at the upcoming American Diabetes Association 80th Scientific Sessions - Virtual (ADA) meeting which will be held from 12-16 June 2020.  Abstract #231-OR will be available online from 14 June 2020

Read the rest of entry »

Evox Therapeutics Announces a Multi-Target RNA Interference and Antisense Research Collaboration and License Agreement With Lilly

Evox Therapeutics Announces a Multi-Target RNA Interference and Antisense Research Collaboration and License Agreement With Lilly

Evox to use its proprietary exosome loading and CNS-targeting technologies to develop oligonucleotide drugs for the treatment of neurological disorders.

Read the rest of entry »

Ethypharm and RSSL partnership fast-tracks priority medicine

Respected scientific and regulatory advisor, Nigel Baldwin, has partnered with RSSL to provide context and guidance on analytical data for new food ingredient submissions.

Read the rest of entry »

OBN Launch OBN Ventures™ An Investment Lifeline in Challenging Times

Abingdon, UK; 28 April 2020 - OBN, the Membership organisation supporting the UK’s innovative life sciences companies, is delighted to announce the launch of OBN Ventures Limited (OBNV).

Read the rest of entry »

RSSL Pharmaceutical training moves online

As concerns around the coronavirus continue to grow, RSSL's top priority is to protect the health and welfare of our tutors, our team and our learners.  It is for this reason that we have made the decision to move all of our March, April and May 2020 training courses online. 
 

Read the rest of entry »

A message from John Harris, CEO of OBN re BioTrinity 2020 & COVID-19

Following the most recent announcements by the Prime Minister in the UK, a Force Majeure situation has been created whereby delivering BioTrinity® as a physical event has now become an impossibility. We will continue to follow all official UK Government and Public Health England advice. The safety, security and interests of our staff, Members and our wider network remains our absolute priority.

Read the rest of entry »

Pages: Previous1234567...22NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.